Emcure Pharmaceuticals announced that its Board of Directors has approved to enter into agreement with minority shareholders of Zuventus Healthcare Ltd., one of its subsidiaries, to acquire their shareholding. Following the completion of this transaction, Zuventus will become a wholly owned subsidiary of Emcure. The transaction is expected to close in Q2 FY 2026.

The domestic market remains a strategic priority for Emcure. This transaction will enable full financial consolidation of Zuventus and drive long-term value creation for Emcure, through alignment across its domestic business and unlock synergies.